{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:17:43Z","timestamp":1777540663508,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals had less neutralizing titer (IC\n                    <jats:sub>50<\/jats:sub>\n                    &amp;lt;50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.797589","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T01:53:24Z","timestamp":1646704404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies"],"prefix":"10.3389","volume":"13","author":[{"given":"Takuya","family":"Tada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie I.","family":"Samanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda M.","family":"Dcosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin S.","family":"Herati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel R.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.Cov2.S Vaccine Against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"New Engl J Med"},{"key":"B3","unstructured":"2021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-Elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0069621","DOI":"10.1128\/mBio.00696-21","article-title":"Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer Against Global SARS-CoV-2 Variant Spikes","volume":"12","author":"Tada","year":"2021","journal-title":"mBio"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 Spike 69\/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2102179","article-title":"Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0131321","DOI":"10.1128\/JVI.01313-21","article-title":"Serum Neutralizing Activity of mRNA-1273 Against SARS-CoV-2 Variants","volume":"95","author":"Choi","year":"2021","journal-title":"J Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108528","article-title":"An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2","volume":"33","author":"Tada","year":"2020","journal-title":"Cell Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022586118","article-title":"The Effect of the D614G Substitution on the Structure of the Spike Glycoprotein of SARS-CoV-2","volume":"118","author":"Benton","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1038\/s41598-021-84913-3","article-title":"Antibody Isotype Diversity Against SARS-CoV-2 is Associated With Differential Serum Neutralization Capacities","volume":"11","author":"Noval","year":"2021","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c Mice for Testing Vaccine Efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S Vaccine Against SARS-CoV-2 Variants in Humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"B19","first-page":"2021.2007.2001.450707","article-title":"Ad26.COV2.S Elicited Neutralizing Activity Against Delta and Other SARS-CoV-2 Variants of Concern","volume-title":"bioRxiv","author":"Jongeneelen","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months After Ad26.COV2.S Vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","article-title":"Heterologous ChAdOx1 Ncov-19 and BNT162b2 Prime-Boost Vaccination Elicits Potent Neutralizing Antibody Responses and T Cell Reactivity","volume-title":"medRxiv","author":"Gross","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune Responses Against SARS-CoV-2 Variants After Heterologous and Homologous ChAdOx1 Ncov-19\/BNT162b2 Vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00420-5","article-title":"Heterologous Prime-Boost Vaccination With ChAdOx1 Ncov-19 and BNT162b2","volume":"21","author":"Tenbusch","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110218","article-title":"The SARS-CoV-2 Lambda Variant Exhibits Enhanced Infectivity and Immune Resistance","volume":"38","author":"Kimura","year":"2022","journal-title":"Cell Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 Spike L452R Variant Evades Cellular Immunity and Increases Infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.797589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T01:53:28Z","timestamp":1646704408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.797589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2022.797589"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.797589","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.19.452771","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"article-number":"797589"}}